Chemo-resistant tumors targeted by BU School of Medicine researcher

(Boston University Medical Center) Rachel Flynn, Ph.D., assistant professor of pharmacology and medicine at Boston University School of Medicine, is the recipient of an Elsa U. Pardee award for approximately $148,000 for 'Targeting the Alternative Lengthening of Telomeres (ALT) Pathway in cancer.' This pathway is frequently reactivated in aggressive cancers such as osteosarcoma and glioblastoma, which are often resistant to standard chemotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news